Wednesday, 5 December 2007

Nine Reasons To Buy Neptune Plus One More!


Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB)


Catalyst Research analyst, Robin Cornwell recently issued an update on the nine reasons he believes Neptune is a buy. We're sure he'd like to see Santa using this list as a stocking stuffer for good boys and girls.

A big part of his list deals with the things he says the market ignored such as the upfront payment from Yoplait and the importance of Dr. Steve Nissen joining the scientific advisory board.

Access the list by clicking here.

Neptune added another reason with today's news that the Therapeutic Goods Administration (TGA) in Australia has approved Neptune Krill Oil (NKO) as a "complementary medicine allowing immediate commercialization in Australia hence New Zealand, which automatically allows TGA approved products."

The point the company stressed in the news release was that this was a breakthrough considering the tough regulatory environment under the TGA. In short, this is a big step for NTB as "complementary medicines are classified as a subset of over-the-counter (OTC) pharmaceuticals" in the TGA jurisdiction.

Today's news should be read in context of Neptune's work in the functional food area as well as it ongoing discussions with pharma companies.

To view the news release click here.